Clinical Trial Update: Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating the combination of orelabrutinib and pemetrexed for relapsed/refractory central nervous system lymphoma and is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Central Nervous System Lymphoma | Phase 2 | Status: RECRUITING